CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genzyme Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genzyme Corporation
500 Kendall Street
Phone: (617) 252-7500p:617 252-7500 Cambridge, MA  02142  United States Ticker: GENZGENZ
This company was Merged or Acquired on 4/8/2011.
This company ceased filing statements with the SEC on 4/18/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Genzyme Corporation (Genzyme) is a biotechnology company. The Company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer and transplant and auto-immune disease. In addition to these areas, Genzyme is developing products focused on cardiovascular disease, neurodegenerative diseases and other areas of unmet medical need. Genzyme operates in five business segments: Personalized Genetic Health (PGH), Renal and Endocrinology, Biosurgery, Hematology and Oncology (HemOnc) and Multiple Sclerosis (MS). In November 2010, it sold its genetics testing business. Its products include Cerezyme, Fabrazyme, Myozyme/Lumizyme, Renagel, Renvela, Hectorol, Synvisc, Synvisc-One, Thymoglobulin and Clolar/Evoltra. In January 2011, it sold diagnostic products business. In February 2011, Genzyme sold pharmaceutical intermediates business. On April 8, 2011, Sanofi-Aventis completed acquired Genzyme.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
---YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
--YesYes-YesYes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer ChristopherViehbacher 51 4/8/2011 4/8/2011
Chief Financial Officer, Executive Vice President - Finance Michael S.Wyzga 55 11/1/2008 2/1/1998
Chief Operating Officer David P.Meeker 56 4/1/2010 5/1/2008
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Caprelsa
GENZ
Genzyme Corporation
10 additional Business Names available in full report.

General Information
Number of Employees: 10,100 (As of 2/22/2011)
Outstanding Shares: 253,558,720 (As of 4/4/2011)
Shareholders: 2,826
Stock Exchange: NASD
Federal Tax Id: 61047163
Fax Number: (617) 252-7600


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024